FactaeThe Factual News

Poxel announces completion of Phase 2 clinical study for MASH

Poxel completes its Phase 2 clinical study for MASH treatment.

Published 2h1 sourceNotableupdated 1h
Lire en français
≈ 16s

The fact

The announcement, scheduled for August 26, 2026, may impact the stock price.

Investors await results to assess the drug's commercial potential.

Click the link to read an article on the topic:
Explore this topic
What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.
FranceWorld map →
Follow topic →
Auto-synthesis from 1 media source · identified on August 24, 2026
← Back to home
Discover

Read more

All marches →
marches

Poxel announces end of phase 2 clinical trial for MASH on September 30

12h · 1 sourcemarches

Poxel presents results at EASD 2026 on Imeglimin

4j · 1 sourcemarches

Poxel postpones publication of its half-year financial results

3sem · 1 sourcemarches

Poxel hit by Merck payment halt: clinical timeline impact

11sem · 1 sourcemarches

Poxel secures Japanese patent for diabetes-targeting molecule

13sem · 1 sourcemarches

CAC 40 in wait-and-see mode before market reopening, several stocks decline

7h · 1 source